$36.57
14.17% yesterday
Nasdaq, May 20, 10:16 pm CET
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Vaxcyte Inc Stock price

$36.57
+6.18 20.34% 1M
-49.39 57.46% 6M
-45.29 55.33% YTD
-39.36 51.84% 1Y
+10.35 39.47% 3Y
+10.42 39.85% 5Y
+10.42 39.85% 10Y
Nasdaq, Closing price Tue, May 20 2025
+4.54 14.17%
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Key metrics

Market capitalization $4.72b
Enterprise Value $3.13b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.47
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-635.87m
Free Cash Flow (TTM) Free Cash Flow $-600.01m
Cash position $1.67b
EPS (TTM) EPS $-4.07
P/E forward negative
Short interest 10.46%
Show more

Is Vaxcyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vaxcyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Vaxcyte Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Vaxcyte Inc forecast:

Buy
100%

Financial data from Vaxcyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 18 18
62% 62%
-
-18 -18
62% 62%
-
- Selling and Administrative Expenses 70 70
54% 54%
-
- Research and Development Expense 530 530
44% 44%
-
-618 -618
45% 45%
-
- Depreciation and Amortization 18 18
62% 62%
-
EBIT (Operating Income) EBIT -636 -636
46% 46%
-
Net Profit -510 -510
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vaxcyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxcyte Inc Stock News

Neutral
GlobeNewsWire
13 days ago
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Compl...
Neutral
GlobeNewsWire
20 days ago
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.
Positive
Seeking Alpha
about 2 months ago
Vaxcyte, Inc.'s positive results achieved from phase 2 dose-finding study using VAX-24 for the prevention of invasive pneumococcal disease in infants; Further post 4 dose data expected 2nd of 2025. It is expected that the 7 major pneumococcal disease markets are to reach a value of $11.6 billion by 2035. VAX-24 goes beyond that of Prevnar 20 in terms of targeting 4 more serotypes than it.
More Vaxcyte Inc News

Company Profile

Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.

Head office United States
CEO Grant Pickering
Employees 414
Founded 2013
Website www.vaxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today